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ABSTRACT
Clinical management of bladder carcinomas (BC) remains a major challenge 
and demands comprehensive multi-omics analysis for better stratification of the 
disease. Identification of patients on risk requires identification of signatures 
predicting prognosis risk of the patients. Understanding the molecular alterations 
associated with the disease onset and progression could improve the routinely used 
diagnostic and therapy procedures. In this study, we investigated the aberrant 
changes in N-glycosylation pattern of proteins associated with tumorigenesis as 
well as disease progression in bladder cancer. We integrated and compared global 
N-glycoproteomic and proteomic profile of urine samples from bladder cancer 
patients at different clinicopathological stages (non-muscle invasive and muscle-
invasive patients [n = 5 and 4 in each cohort]) with healthy subjects (n = 5) using 
SPEG method. We identified 635 N-glycopeptides corresponding to 381 proteins and 
543 N-glycopeptides corresponding to 326 proteins in NMIBC and MIBC patients 
respectively. Moreover, we identified altered glycosylation in 41 NMIBC and 21 MIBC 
proteins without any significant change in protein abundance levels. In concordance 
with the previously published bladder cancer cell line N-glycoproteomic data, we also 
observed dysregulated glycosylation in ECM related proteins. Further, we identified 
distinct N-glycosylation pattern of CD44, MGAM, and GINM1 between NMIBC and MIBC 
patients, which may be associated with disease progression in bladder cancer. These 
aberrant protein glycosylation events would provide a novel approach for bladder 
carcinoma diagnosis and further define novel mechanisms of tumor initiation and 
progression.
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INTRODUCTION
Bladder carcinoma is one of the most common 
urothelial cancers worldwide with high morbidity and 
mortality of 2,000,000 (GLOBOCAN, 2018). Patients are 
predominantly diagnosed with non-muscle invasive bladder 
cancer carcinoma (NMIBC) is the prevalent type (70–75%) 
and is defined as a superficial neoplasia. These tumors are 
restricted to the mucosal or sub mucosal layer with high risk 
of recurrence [1]. About, 10–20% of NMIBC will progress 
into muscle invasive bladder carcinoma (MIBC) which 
has a high risk of metastasis and is characterized by poor 
prognosis [2]. Accurate staging, grading, risk stratification is 
essential for disease management and better clinical outcome 
of the patients [3]. Presently the major diagnosis methods of 
bladder carcinoma are imaging tests (such as ultrasound, CT, 
MRI), cystoscopy, and urine cytology. However, they lack 
either precision or sensitivity mostly in NMIBCs. Hence, 
high recurrence rate and high costs in clinics are the major 
challenges in the management of this cancer. Identifying the 
precise, non-invasive, economical, and convenient methods 
as well as a highly robust biomarker for bladder carcinoma 
diagnosis is the booming need of this era. The best choice a 
novel non-invasive, affordable method for diagnosis, as well 
as for monitoring disease progression after treatment as well 
as for predicting prognosis would be through urine-based 
detection methods [4].
Glycosylation of proteins has an impact on many 
biological functions such as protein folding, trafficking, 
endocytosis, cell adhesion, receptor activation, immune 
functions [5]. Altered glycosylation has been aligned 
with carcinogenesis, progression of the disease, tumor 
associated invasion, sensitivity to treatment [6–9]. 
Cancer specific changes in glycosylation can serve as 
diagnostic as well as therapeutic targets, for instance 
aberrant N-glycosylation of serum Immunoglobulins 
(Igs) urothelial carcinoma suggests glycosylation pattern 
as diagnostic biomarker [10, 11]. Dysregulation of protein 
glycosylation has been associated with cancer hallmarks 
in bladder cancer [12, 13]. Dysregulated glycosylation 
of extracellular matrix proteins has been reported 
in aggressive non-type subtype bladder cancer cells 
compared to basal/ luminal type [14].
In this study, we have compared the urinary 
N-glycoproteomic and proteomic profile of NMIBC and 
MIBC along with control groups. We employed tandem 
mass tag (TMT) labelling method for quantitation along 
with the solid phase extraction of N-linked glycopeptide 
(SPEG) for the enrichment. Combining these cutting-edge 
sample preparation techniques with high resolution mass 
spectrometry enable us to identify urinary proteomic and 
N-glycosylation alterations in the NMIBC and MIBC. To 
our knowledge, this is the first report on the combining 
proteomic and N-glycoproteomic analysis from urine from 
muscle invasive and non-invasive bladder cancer patients 
and control samples.
RESULTS
Global proteomic and N-glycoproteomic 
profiling of bladder carcinoma patients
For the understanding of the alteration in the 
proteome and N glycosylation associated with bladder 
carcinoma, we performed LC-MS/MS-based quantitative 
N-glycoproteomics and proteomics analysis of urine 
samples collected from healthy subjects (n = 5), non-
muscle invasive (n = 5) and muscle invasive (n = 4) 
bladder carcinoma patients. The work flow of the 
experiment is schematically illustrated in Figure 1. We 
identified a total of 590 proteins and 763 N-glycopeptides 
(Supplementary Figure 1A and 1B).
Global quantitative urinary N-glycoproteomic 
and proteomic analysis of non-muscle invasive 
bladder cancer patients
We compared the N-glycoproteomic and proteomic 
profile of urine samples from NMIBC patients and the 
healthy subjects. N-glycopeptide enrichment of the 
pooled labeled samples were carried out using solid phase 
extraction of glycopeptides (SPEG). This leads to the 
identification of 635 N-linked glycopeptides corresponding 
to 381 proteins. We quantified 625 glycopeptides 
corresponding to 378 glycoproteins across all the samples 
(Supplementary Table 2) (Figure 2A). From the quantified 
glycopeptides we observed differential N-glycosylation of 
201 N-linked glycopeptides corresponding to 164 proteins 
(p-value < 0.05). Unsupervised clustering revealed distinct 
N-glycosylation pattern between the cohorts (Figure 2B).
From our global proteomic data, we identified 543 
proteins of which 485 proteins are quantified across all the 
samples (Supplementary Table 3). The quantified proteins 
are represented in volcano plot (Figure 2C). Statistical 
analysis (t-test) revealed 177 proteins to be significantly 
altered (p-value < 0.05) between the cohorts (Figure 2D).
To identify if the changes were because of alteration 
in protein abundance or in glycosylation site occupancy, 
we compared the glycoprotein changes identified from our 
glycoproteomic analysis to those identified from our global 
proteomic analysis. We compared the N-glycosylation 
fold change against the total protein fold change. We 
identified 41 differentially glycosylated proteins without 
any changes in protein abundance (Figure 2E).
Quantitative urinary proteomic and 
glycoproteomic analysis of muscle invasive 
bladder carcinoma patients
We further compared N-glycoproteomic and 
proteomic profiling of MIBC patients with healthy 
individuals. Glycoproteome profiling of MIBC 
patient urine samples resulted in identification of 543 
Oncotarget3246www.oncotarget.com
Figure 1: Integrated proteomics and N-glycoproteome analysis workflow applied to urine samples from bladder 
cancer patients and healthy subjects. Following filtration with 3kDA filters, urinary proteins were concentrated and digested with 
trypsin. Each sample was labeled with 10-plex Tandem Mass Tags (TMT) labeling kit and pooled. One-tenth of the pooled sample was used 
for global proteomics experiment and remaining was enriched for N-glycoproteomic analysis. Samples were analyzed in Q Exactive HF-X 
Hybrid Quadrupole-Orbitrap mass spectrometer and the files were searched against Mascot and Sequest HT search engines. Data analysis 
was carried out using Perseus. exe 1.6.5.0.
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N-glycopeptides corresponding to 326 proteins and 
quantified 537 glycopeptides (Supplementary Table 4), 
which mapped to 322 proteins (Figure 3A). From the 
quantified 537 peptides we identified of 82 glycopeptides 
corresponding to 65 were differentially glycosylated 
in MIBC compared to healthy group (p-value < 0.05) 
(Figure 3B).
From our global proteomic data, we identified 486 
proteins and 427 (Supplementary Table 5) proteins are 
quantified across all the samples (Figure 3C). Further, 72 
quantified proteins (p-value < 0.05) were differentially 
expressed (Figure 3D). The integrative analysis of the 
proteomic and glycoproteomic data revealed differential 
glycosylation of 21 proteins without any change at total 
protein expression level (Figure 3E).
Comparison of N-glycoproteomic patient data 
with previously published cell line data
In our previous study by Deb et al., we reported 
distinct glycosylation profile between the basal/luminal 
and non-type bladder cancer cell lines [14]. To assess 
the concordance between the urinary N-glycoproteome 
data along with previously published cell line data, we 
compared the cell line data with the commonly expressed 
glycosylation site between NMIBC and MIBC. We 
identified site-specific glycosylation in 2 sites of GAA 
(390, 470) and 1 site of ICAM1 (260) (Figure 4A). 
We further compared the glycosylation profile of less 
aggressive basal/ luminal with NMIBC patients and 
aggressive non-type cell lines with MIBC patients. We 
Figure 2: Urinary N-glycoproteome and proteome of NMIBC. (A) Volcano plot of N-glycoproteome of NMIBC and normal 
subjects. Fold change of the N-glycosylation abundances (log2) are plotted against the t-test p-values (-log10). Significance levels are 
marked by dashed lines. (B) Unsupervised clustering of dysregulated N-glycopeptides identified in NMIBC and healthy subjects. t-test 
between the two cohorts revealed dysregulation of N-glycosylation in 201 glycopeptides. Abundance values of differentially glycosylated 
peptides are represented in heatmap. (C) Volcano plot represents the proteomic profile of NMIBC and healthy subjects. Fold change of 
proteins (log2) expressed in NMIBC patients were calculated with respect to the healthy subjects and plotted against the t-test p-value 
(-log10). Dashed lines represent the significance levels. (D) Heat map represents the abundances of differentially expressed proteins 
between the NMIBC and healthy subjects. (E) Global presentation of proteomic and respective glycosylation occupancy. Yellow datapoints 
represent differential glycosylation occupancy with fold change ≥ 1.5 and blue datapoints with fold change ≥ 2 on proteins that are 
unchanged in proteomic data. Grey datapoints represent proteins that are unchanged in both datasets.
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found that 9 site specific glycosylation of FGFR1 (329), 
FN1 (1007), GAA (390), ICAM1 (260), NCAM1 (485), 
PSAP (335), PTPRJ (335), GAA (470) and PLBD1 
(470) are common for basal/luminal cell line vs NMIBC 
patient data (Figure 4B). Similarly, we also compared 
the non-type cell line data with MIBC patient data and 
identified 5 site-specific glycosylation across the groups. 
N-glycosylation of the all the 5 proteins namely, CD276 
(91), BTD (152), GAA (390), ICAM1 (260) and PTPRJ 
(149) were downregulated in MIBC compared with the 
control groups (Figure 4C).
Comparison between the N-glycoproteome and 
proteome of NMIBC and MIBC patients
Comparing the N-glycoproteome and global 
proteomic expression could reveal the stage specific 
glycoproteomic and protein expression pattern in bladder 
carcinoma patients. We compared the differentially 
glycosylated peptides between NMIBC and MIBC 
and identified glycosylation of 46 N-glycopeptides 
corresponding to 41 proteins (Figure 5A, Supplementary 
Table 6). Statistical analysis of the commonly glycosylated 
proteins revealed significant alteration of glycosylation 
in 8 proteins between NMIBC and MIBC. Of these 
proteins such as COL6A1(212), FBN1(2734), GAA (470) 
show significant glycosylation without any change in 
protein expression both in NMIBC and MIBC patients. 
Glycosylation of GINM1(46) is downregulated in NMIBC 
without any change in protein expression level. We 
observed altered glycosylation of CD44 (57) and MGAM 
(2499) in MIBC patients without any significant change in 
protein expression.
Reactome pathway analysis revealed 
dysregulation of oncogenic pathways in bladder 
carcinoma
We further carried out Reactome pathway analysis 
with the 164 differentially glycosylated proteins in NMIBC 
Figure 3: Urinary N-glycoproteome and proteome of MIBC. (A) Volcano plot shows the N-glycoproteome profile of MIBC 
and healthy subjects. Fold change of the N-glycosylation abundances (log2) are plotted against the t-test p-values (-log10). Significance 
levels are indicated by dashed lines. (B) Heat map representing the significantly glycosylated peptides in MIBC group in comparison with 
the healthy subjects (p-value < 0.05). Abundance values of the differentially glycosylated peptides are represented in the heat map. (C) 
Volcano plot represents comparative proteomic profile of MIBC and healthy subjects. Fold change of the protein abundances versus t-test 
p-values (-log10). Significance levels are indicated by dashed lines. (D) Heat map of differentially expressed proteins (log2 abundance 
value) of MIBC compared with the healthy subjects. (E) Global presentation of proteomic and respective glycosylation occupancy. Yellow 
datapoints represent differential glycosylation occupancy with fold change ≥ 1.5 and red datapoints with fold change ≥ 2 on proteins that 
are unchanged in proteomic data. Grey datapoints represent proteins that are unchanged in both datasets.
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and 65 differentially glycosylated proteins of MIBC. Top 5 
enriched pathways are listed in Figure 5B. Pathways such 
as “extracellular matrix organization” (p-value = 9.57E-
11, 4.6E-9; FDR = 4.19E-08, 5.84E-7), “post-translational 
protein phosphorylation” (p-value = 2.22E-09, 1.99 E-10; 
FDR = 4.87E-07, 1.01 E-7) and neutrophil degranulation 
(p-value = 2.90E-10, 2.36E-09; FDR = 8.47E-08, 3.99E-
07) were dysregulated in NMIBC as well as MIBC 
patients (Supplementary Table 7).
DISCUSSION
Bladder carcinoma management is contingent on 
stratification of patients based on their clinicopathological 
subtype, probability of recurrence and progression of the 
disease. Molecular complexity is often a major contributor 
for creating a hindrance in clinical diagnosis as well as 
treatment resolutions. PTMs, add the complexity of 
a protein, however, they also potentially offer novel 
Figure 4: Comparison between cell line and our clinical data. (A) Comparison between the previously published cell line data 
and the clinical data identified site-specific glycosylation of 3 proteins common between the data. Box plot represents the regulation of the 
proteins in healthy subjects, NMIBC (T1) and MIBC (T2) patients. (B) Comparing the N-glycoproteome of basal/luminal bladder cancer 
cell lines and the NMIBC patients identified site specific glycosylation of 9 proteins. Regulation of the glycosylation between the NMIBC 
and healthy subjects are shown in box plot. (C) Comparing the N-glycoproteome of non-type bladder cancer cell lines and the NMIBC 
patients identified site specific glycosylation of 5 proteins. Regulation of the glycosylation between the NMIBC and healthy subjects are 
shown in box plot.
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diagnostic and targeting opportunities across tumor sub-
populations. Profiling these PTMs such as glycosylation 
from cancer patients’ samples would eventually lead 
to expanding the knowledge repertoire from better 
mechanistic studies. Hence, in this study, we carried out 
comparative N-glycoproteomic and proteomic profiling of 
urine samples from NMIBC and MIBC patients, as it is the 
most widely used non-invasive specimen for BC diagnosis 
and monitoring. Here, we utilized TMT-based proteomic 
approach to demonstrate the dysregulated glycosylation 
and differentially expressed proteins in BC.
For a comprehensive glycosylation profile of 
BC and dissecting the unique patterns in NMIBC and 
MIBCs, combining the global protein expression data 
was inevitable. Thus, we integrated the glycoproteomic 
and proteomic data of NMIBC patients and among the 41 
proteins underwent glycosylation without any significant 
changes in protein expression levels. Metalloproteinase-8 
(MMP8), cluster of differentiation 59 (CD59), 
apolipoprotein H (APOH), fibrinogen beta chain precursor 
(FGB), Fibrillin-1 (FBN1), and S100A1, a few to mention. 
High mRNA level of MMP8 has been reported in bladder 
cancer and is positively correlated with tumor grade [15]. 
In this study, we observed MMP8 is heavily glycosylated 
in NMIBC patients compared to the healthy subjects. High 
expression of FBN1 has been reported in bladder cancer 
patients and associated with worst overall survival [16]. 
FBN1 is also known to induce metastasis in ovarian cancer 
Figure 5: Comparison between N-glycoproteome and proteome of NMIBC and MIBC patients. (A) Heatmap representing 
the differentially glycosylated peptides in NMIBC and MIBC patients. Highlighted are the proteins with significant glycosylation (> 2-fold) 
without any change in protein expression level. (B) Top 5 enriched pathways in NMIBC and MIBC patients. Reactome analysis identified 
integrin cell surface interaction as most enriched in NMIBC and post-translational modification as most enriched pathway in MIBC.
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[17]. Recently, the role of complement system in cancer 
progression is widely studied. The complement factor C3, 
which is known to be associated with tumor progression is 
highly glycosylated in our study. It has been hypothesized 
that cancer cells escape from complement system by 
activating complement inhibitors, such as CD59, CD46, 
and CD55. The membrane complement inhibitor CD59 
expression has been reported to be upregulated in many 
cancers including bladder and is correlated with cell 
proliferation, apoptosis and immune evasion [18–21]. The 
altered glycosylation in complement system proteins and 
their inhibitors might be aiding the tumor cells to evade 
the immune system and leading to tumorigenicity.
In addition, comparison between the 
glycoproteomic and proteomic data of MIBC patients 
revealed the dysregulation of glycosylation in 21 proteins 
without any alterations in protein expression. Some of 
these proteins include, vitronectin (VN), fibrinogen beta 
chain protein (FGB), myeloperoxidase (MPO), serpin 
family C member 1 (SERPINC1), cadherin13 (CDH13). 
VN that functions as an adhesive molecule between the 
cells and ECM has been reported in cancers for cell 
growth, angiogenesis and metastasis [22]. A recent study 
has demonstrated VN is a potent promigratory factor 
and its activity is inhibited by fibrinogen [23]. In our 
data, we observed altered glycosylation of VN and FGB 
without any significant change in protein expression 
level. Przybyło et al., postulated altered glycosylation in 
cadherins interrupt the effective interactions between the 
cells in bladder cancer [24]. Downregulation of CDH13 
expression promotes invasiveness of bladder transitional 
cell carcinoma [25].
In this study, we conducted a broad analysis of the 
differentially expressed proteins as well. Interestingly, 
altered expression levels of ECM and immune system 
related proteins were observed in NMIBC data. MMP-
9 was elevated in the urine samples of BC patients and 
has been associated with tumor growth, invasion and 
metastasis [26, 27]. High expression of complement 
proteins has been associated with tumor growth, evasion 
from immune surveillance, metastasis and EMT in various 
cancers [28]. Complement proteins such as C3, C4A, 
CFB were highly expressed in NMIBC patient samples. 
Altered N-glycosylation and expression of these proteins 
may promote carcinogenesis by regulating tumor initiating 
events such as proliferation and immune evasion in BC. 
We also observed high expression of S100 family proteins 
such as S100A8, S100A9, S100P and S100A12 in MIBC 
patients. Altered expression of S100 proteins has been 
correlated with progression of various cancers [29, 30].
In our previous study by Deb et al., we carried 
out N-glycoproteomic profiling of basal/luminal as well 
as aggressive non-type bladder carcinoma cell lines. 
Glycoproteomic profiling of bladder cancer cell lines 
identified altered glycosylation of extracellular matrix 
associated proteins in non-type cells compared with the 
basal/luminal cells [14]. We compared our patient data 
with the cell line data to check the concordance of cell 
line and clinical data sets. Interestingly, we identified site-
specific glycosylation of 9 proteins between NMIBC and 
basal/luminal cell lines and 5 between the MIBC patients 
and non-type cell lines. Higher glycosylation of FN1 was 
observed in NMIBC patient cohort and its glycosylation 
has been reported to be involved in positive regulation of 
cell adhesion and directing cell migration [31]. ICAM1, 
which is identified in cell lines as well as patients’ urine 
data, is known to promote tumorigenesis and increase the 
metastatic potential of cancer cells [32].
Further, to identify the pattern of N-glycosylation 
and protein expression associated with disease progression 
we compared the N-glycoproteome as well as proteome 
data of NMIBC and MIBC patients. However, we could 
not identify significant number of proteins with a unique 
glycosylation trend across the NMIBCs or MIBCs. This is 
also quite intuitive that MIBCs and NMIBCs would have 
a similar molecular profile as they are progression stages 
and though the clinical manifestation is distinct it may 
not reflect similarity in molecular regulation. We found 
significant glycosylation in proteins such as fibrillin-1 
(FBN1), collagen type VI alpha 1 chain (COL6A1) and 
glucosidase alpha acid (GAA) both in NMIBC and MIBC 
patients. Survival analysis of bladder cancer patients 
revealed elevated expression COL6A1 and FBN1 is 
associated with a worse overall survival and progression 
of disease [16]. We observed unique glycosylation of 
glycoprotein integral membrane 1 (GINM1) in NMIBC 
patients, however the role of this protein in cancer 
development or progression is not yet reported. We also 
observed unique glycosylation of maltase-glucoamylase 
alpha-glucosidase (MGAM) and cluster of differentiation 
44 (CD44) in MIBC patients. CD44 is overexpressed in 
several cancers and is a molecular marker for stem cells 
[33, 34]. High expression of CD44 has been associated 
with higher clinical stage and aggressiveness in bladder 
cancer [35]. CD44 can bind to its ligand hyaluronic 
acid (HA) and is known to activate cell proliferation, 
invasion, migration [33]. It has been shown that changes 
in glycosylation of CD44 can affect its interaction with 
HA and glycosylation may also be a regulatory mechanism 
for CD44 function [36]. Also, CD44 is involved in 
activating various oncogenic events in cancer tissues 
through activation of signaling pathways such as PI3K/ 
AKT and RhoGTPase. Activation of these pathways 
promotes angiogenesis, survival, invasion and promotes 
tumor progression [37]. The unique glycosylation of CD44 
in MIBC patients may account for the tumorigenic and 
tumor progression processes, however further validations 
has to be carried out.
The pathway analysis of NMIBC patients revealed 
dysregulation of pathways such as integrin cell surface 
interaction, extracellular matrix organization, neutrophil 
degranulation, post translational protein phosphorylation 
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and platelet degranulation as top five. In MIBC patients 
we observed dysregulation of pathways such as post 
translational protein phosphorylation, regulation of IGF like 
growth factor transport and uptake by IGFBPs, neutrophil 
degranulation, extracellular matrix organization and IGF2 
bind RNA. Among these extracellular matrix organization 
pathway and neutrophil degranulation pathways are found 
to be dysregulated in both stages. The role of ECM proteins 
in development of invasion, progression and metastasis of 
bladder cancer is widely studied [38].
We observed a clear difference between the 
glycosylation profile and protein expression among the 
control and tumor groups. We hypothesized that differential 
glycosylation of proteins between the NMIBC results in 
tumorigenic processes whereas the differential glycosylation 
in MIBC may be associated with tumor progression. 
However, most of the differentially glycosylated proteins 
are commonly dysregulated in NMIBC and MIBC patients 
suggesting an overlap of molecular events of the disease.
MATERIALS AND METHODS
Patient sample collection
Urine samples were collected from patients confirmed 
with bladder carcinoma enrolled in All India Institute 
of Medical Science (AIIMS), Delhi. The urine for the 
control group is collected from healthy volunteers with 
consent. The study was conducted in accordance with 
the ethical requirements and the project was approved by 
the Ethics Committee (Project identification code: IEC-
372/07.07.2017). Voided urine samples and associated 
clinical information is summarized in Supplementary 
Table 1. For the initial screening, voided urine was collected 
from healthy subjects and bladder carcinoma patients in 
50 ml centrifuge tubes. The voided urine was clean catch, 
midstream urine, and the samples did not contain squamous 
cells or microbes. The samples collected from the healthy 
individuals (the control group), were confirmed with 
no previous history of urothelial cell carcinoma, gross 
hematuria, active urinary tract infection or urolithiasis. After 
collection, 15 ml urine from each sample was centrifuged 
at 7000 g for 15 minutes at 4°C to remove the cell debris. 
Supernatant was collected, concentrated to 500 µl in 3 kDa 
filters. The concentrated urine was stored at –80°C until use.
Protein digestion and TMT peptide labeling
Protein amount was estimated using BCA 
(Bicinchoninic Acid) protein assay. From all samples 
100 µg of protein from each sample were reduced, 
alkylated and precipitated with 10 mM (dithiothreitol) 
DTT, 20 mM iodoacetamide (IAA) and ice-cold acetone. 
The precipitated samples were then resuspended in 50 
mM triethyl ammonium bicarbonate (TEABC) and 
digested with trypsin (1:20, Promega) 12–16 h at 37°C. 
Resulting peptides were cleaned using Sep-Pak C18 
material (Waters, Catalog # WAT023501). Peptides from 
corresponding samples were labeled with 10 plex TMT 
labels according to manufacturer’s protocol.
N-Glycan enrichment
Glycopeptides were enriched directly by employing 
solid-phase extraction of N-glycopeptides method as 
described previously [39]. Glycopeptides from the tryptic 
peptide digest were enriched using solid-phase extraction 
of glycosite-containing peptides (SPEG). Briefly, 90% of 
the TMT-labeled tryptic peptides (1 mg) were dissolved 
in 5% ACN in 0.1% TFA followed by adding 1/10 of the 
final volume of 100 mM sodium periodate to the samples. 
These were incubated in the dark at room temperature for 
1 hour with gentle shaking. After this step, peptides were 
cleaned using C18 clean-up. For the experiment, 200 µL of 
the 50% hydrazide resin (Bio-Rad Laboratories, Hercules, 
CA, USA) were used. Hydrazide resin beads were further 
washed three times with 1 ml deionized water. Following 
this, peptides along with 1% Aniline were added to 
the beads (pH < 6). The samples were incubated with 
hydrazide beads for one hour at room temperature in the 
dark with gentle shaking. Beads were then washed to 
remove any nonspecific binding. PNGaseF (New England 
Biolabs, Ipswich, MA, USA) was used to detach glycosite-
containing peptides from glycans conjugated on the beads. 
The supernatant containing N-linked glycopeptides were 
collected and dried using vacufuge. These enriched 
N-linked glycopeptides were directly used for the mass 
spectrometric analysis.
LC-MS/MS analysis
The peptides and enriched glycopeptides were 
analyzed on Q Exactive HF-X Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific, Bremen, 
Germany) interfaced with Dionex Ultimate 3000 nanoflow 
liquid chromatography system. Peptides were separated 
on an analytical column (75 µm × 50 cm, RSLC C18) at 
a flow rate of 300 nl/min using a gradient of 8%–35% 
solvent B (0.1% formic acid in 90% acetonitrile) for 105 
min. The total run time was set to 120 min. The mass 
spectrometer was operated in a data-dependent acquisition 
mode. The precursor scan MS scan (from m/z 350–1600) 
was acquired in the Orbitrap at a resolution of 120,000 
at 200 m/z. The automatic gain control (AGC) target 
for MS1 was set as 3 × 106 and ion filling time set at 
50 ms. The most intense ions with charge state ≥ 2 was 
isolated and fragmented using HCD fragmentation with 
32% normalized collision energy and detected at a mass 
resolution of 45,000 at 200 m/z. The AGC target for MS/
MS was set as 5 × 105 and ion filling time set at 150 ms, 




The acquired mass spectrometry data were searched 
against Human RefSeq protein database (version 81, 
containing protein entries with common contaminants) 
using SEQUEST search algorithm through Proteome 
Discoverer platform (version 2.1, Thermo Scientific). 
Following search parameters were used: two missed 
cleavages allowed, trypsin as cleavage enzyme, a tolerance 
of 10 ppm on precursors and 0.02 Daltons on the fragment 
ions. Fixed modification includes: carbamidomethylation 
at cysteine, TMT 10‐plex (+229.163) modification at N‐
terminus of peptide and lysine and variable modification 
as oxidation of methionine and deamination of asparagine 
and glutamine. Data was also searched against a 
decoy database and filtered with a 1% false discovery 
rate (FDR). Glycopeptides were further filtered for 
consensus sequence of N-linked glycosylation motif 
NXS/T. Protein centric glycosylation site were inferred 
using in house PERL script. The relative abundance of 
N-glycoproteins was calculated. The mass spectrometry 
data generated from this study have been deposited 
to the ProteomeXchange Consortium (http://www.
proteomexchange.org) via PRIDE partner repository with 
the dataset identifier PXD020078.
Statistical analysis
For the identification of glycopeptides differentially 
glycosylated between NMIBC and MIBC, two sample 
“t-test” with unequal variances (p < 0.05) was used. This 
led to the identification of a list of glycoproteins which 
were further used for pathway and network analysis.
Reactome pathway analysis
Reactome analysis tool (http://www.reactome.
org) was used to identify the enriched pathways in the 
NMIBC and MIBC patients using the set of differentially 
glycosylated peptides (p ≤ 0.05) (https://www.reactome.
org/ PathwayBrowser/#TOOL=AT).
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